Drugs / paquinimod
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01487551 | Dec 2011 → Feb 2013 | systemic sclerosis | Active Biotech AB | Completed | No outcome recorded |
| Phase 2 | NCT00997100 | Aug 2009 → Sep 2010 | systemic lupus erythematosus | Active Biotech AB | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | paquinimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01487551 ↗ |
| Known as | ABR-215757 | ChEMBL registry synonym — accepted as the source's own label CHEMBL67776 ↗ |
| Modality | Small molecule | — CHEMBL67776 ↗ |
| Route | Oral | “paquinimod, an oral immunomodulatory compound” PMID 34330322 ↗ Jul 2021 |